Net revenues grew 22.1% year-over-year to $11.8 million.
Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.
CEO Linda Tharby announced retirement and transition to advisory role.
Amended credit facility extends maturities and lowers interest rate floor.
The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and persistent operational inefficiency. KORU's ability to grow its international footprint and penetrate the pharma services market is a powerful signal of product-market fit for the FREEDOM System. The narrowing of net losses suggests that the company is beginning to find a path toward operating leverage, provided it can stabilize its cost structure. However, the trade-off for this growth is a tightening of the balance sheet and a decline in gross margins. The recent credit facility amendment provides a necessary safety net, but the new liquidity covenants place a premium on the company's ability to achieve positive EBITDA quickly. Investors must weigh the impressive 22% revenue growth against the risks of leadership transition and the volatility of clinical trial-based revenue streams to determine if the scaling narrative is sustainable.